This trial is active, not recruiting.

Condition hyperkalemia
Treatment sodium zirconium cyclosilicate
Phase phase 3
Sponsor ZS Pharma, Inc.
Start date June 2014
End date October 2016
Trial size 750 participants
Trial identifier NCT02163499, ZS-005


The Open-Label Maintenance Study contains an Acute Phase, in which subjects will be dosed with ZS 10 g three times daily (tid) for 24 to 72 hours, followed by a long-term Maintenance Phase.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose supportive care
Open label oral administration of sodium zirconium cyclosilicate 10g once daily for up to 12 months.
sodium zirconium cyclosilicate ZS
Oral 10g once daily with breakfast for up to 12 months.

Primary Outcomes

Safety and Tolerability of long-term dosing with ZS.
time frame: Up to 12 months

Secondary Outcomes

The proportion of subjects who can maintain normokalemia.
time frame: Up to 12 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Provision of written informed consent. - Over 18 years of age. - Two consecutive i STAT potassium values, measured 60 (+/- 15) minutes apart, both >/= 5.1 mmol/L and measured within 1 day before the first dose of ZS on Acute Phase Study Day 1. - Ability to have repeated blood draws or effective venous catheterization. - Women of childbearing potential must be using 2 forms of medically acceptable contraception (at least 1 barrier method) and have a negative pregnancy test at Acute Phase Study Day 1. Women who are surgically sterile or those who are postmenopausal for at least 2 years are not considered to be of childbearing potential. - Controlled diabetic subjects. Exclusion Criteria: - Pseudohyperkalemia signs and symptoms, such as hemolyzed blood specimen due to excessive fist clenching to make veins prominent, difficult or traumatic venipuncture, or history of severe leukocytosis or thrombocytosis. - Subjects treated with lactulose, rifaximin, or other non-absorbed antibiotics for hyperammonemia within 7 days prior to first dose of ZS on Acute Phase Study Day 1. - Subjects treated with sodium polystyrene sulfonate (SPS; eg, Kayexalate®) or calcium polystyrene sulfonate (eg, Resonium®) within 3 days prior to first dose of ZS on Acute Phase Study Day 1. - Subjects with a life expectancy of less than 12 months. - Subjects who are severely physically or mentally incapacitated and who, in the opinion of investigator, are unable to perform the subjects' tasks associated with the protocol. - Women who are pregnant, lactating, or planning to become pregnant. - Subjects with diabetic ketoacidosis. - Presence of any condition which, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated. - Known hypersensitivity or previous anaphylaxis to ZS or to components thereof. - Treatment with a drug or device within the last 30 days that has not received regulatory approval at the time of study entry. - Subjects with cardiac arrhythmias that require immediate treatment. - Subjects on dialysis. - Subjects randomized into the previous ZS-002, ZS-003, ZS-004, or ZS-004E studies. - Documented GFR <15 mL/min within 90 days prior to study entry.

Additional Information

Official title Multicenter, Multi-Dose, Open-Label Maintenance of Long-Term Safety and Efficacy of Sodium Zirconium Cyclosilicate (ZS) in Hyperkalemia
Description Subjects with 2 consecutive i STAT potassium values 5.1 mmol/L will enter the Acute Phase and receive ZS 10 g tid for 24 to 72 hours, depending on potassium values. Once normokalemia (i STAT potassium between 3.5 and 5.0 mmol/L, inclusive) is restored (whether after 24, 48 or 72 hours), subjects will be enrolled in the Maintenance Phase to be dosed with ZS at a starting dose of 10 g qd. Potassium (i STAT and central laboratory) will be measured weekly throughout the first month of study and every 4 weeks thereafter through Month 12. During the Maintenance Phase, the ZS dose may be increased or decreased in increments/decrements of 5 g qd up to a maximum of 15 g qd or a minimum of 5 g every other day based on i STAT potassium measurements as outlined below: - > 5.5 mmol/L: increase ZS dose to 15 g qd (if the 10 g dose was well tolerated) - Between 3.0 and 3.4 mmol/L, inclusive: decrease ZS dose in 5 g qd decrements to a minimum dose of 5 g every other day; if a subject's i STAT potassium value remains between 3.0 and 3.4 mmol/L, inclusive, on the ZS 5 g every other day dose, the subject will be withdrawn from the study and receive standard of care treatment. There is no limit to the number of dose titrations allowed. Subjects will receive up to 12 months of treatment with open-label ZS.
Trial information was received from ClinicalTrials.gov and was last updated in May 2016.
Information provided to ClinicalTrials.gov by ZS Pharma, Inc..